The effect of doubling the dose of acetylsalicylic acid (ASA) on platelet function parameters in patients with type 2 diabetes and platelet hyperreactivity during treatment with 75 mg of ASA: A subanalysis of the AVOCADO study

Kardiologia Polska

Volumn 71, Issue 6, 2013, Pages 552-557

  Rosiak, Marek ^a   Postula, Marek ^a   Kaplon Cieslicka, Agnieszka ^a   Trzepla, Ewa ^a   Filipiak, Krzysztof J ^a   Czlonkowski, Andrzej ^a   Opolski, Grzegorz ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Antiplatelet drugs; Aspirin resistance; Platelet activation

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; ANGIOTENSIN RECEPTOR ANTAGONIST; AREPLEX; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT; PROTON PUMP INHIBITOR; THROMBOXANE B2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD CHEMISTRY; BLOOD CLOTTING PARAMETERS; BLOOD SAMPLING; CLINICAL ASSESSMENT; COLLAGEN EPINEPHRINE INDUCED CLOSURE TIME; CONTROLLED STUDY; DIABETIC PATIENT; DRUG EFFICACY; DYSLIPIDEMIA; FEMALE; HIGH PLATELET REACTIVITY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PLATELET REACTIVITY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REACTION TIME; THROMBOCYTE ACTIVATION; THROMBOCYTE DISORDER; THROMBOCYTE FUNCTION; THROMBOCYTE FUNCTION ANALYZER; THROMBOCYTE FUNCTION TEST; TREATMENT DURATION; URINALYSIS;

EID: 84879958722     PISSN: 00229032     EISSN: None     Source Type: Journal    
DOI: 10.5603/KP.2013.0056     Document Type: Article

References (16)

1. Stein B, Weintraub WS, Gebhart SP et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation, 1995; 91: 979-989.
2. Standards of medical care in diabetes-2011. Diabetes Care, 2011; 34 (suppl. 1): S11-S61.
3. Czech A, Cypryk K, Czupryniak L, Grzeszczak W. Zalecenia kliniczne dotycza̧ce postȩpowania u chorych na cukrzycȩ 2011. Stanowisko Polskiego Towarzystwa Diabetologicznego. Diabetologia Praktyczna, 2011; 12 (suppl. A): 46.
4. Michelson AD, Cattaneo M, Eikelboom JW et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost, 2005; 3: 1309-1311.
5. Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol, 2005; 46: 1705-1709.
6. Postula M, Kaplon-Cieslicka A, Rosiak M et al. Genetic determinants of platelet reactivity during acetylsalicylic acid therapy in diabetic patients: evaluation of 27 polymorphisms within candidate genes. J Thromb Haemost, 2011; 9: 2291-2301.
7. Homoncik M, Jilma B, Hergovich N et al. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost, 2000; 83: 316-321.
8. Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med, 2001; 138: 152-163.
9. Lordkipanidze M, Pharand C, Schampaert E et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J, 2007; 28: 1702-1708.
10. Mortensen SB, Larsen SB, Grove EL et al. Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus. Thromb Res, 2010; 126: e318-e322.
11. Capodanno D, Patel A, Dharmashankar K et al. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circ Cardiovasc Interv, 2011; 4: 180-187.
12. Gurbel PA, Bliden KP, DiChiara J et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation, 2007; 115: 3156-3164.
13. Reny JL, De Moerloose P, Dauzat M, Fontana P. Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost, 2008; 6: 444-450.
14. Simpson SH, Gamble JM, Mereu L, Chambers T. Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysis. J Gen Intern Med, 2011; 26: 1336-1344.
15. Michelson AD. Methods for the measurement of platelet function. Am J Cardiol, 2009; 103 (3 suppl.): 20A-26A.
16. Mezzano D, Quiroga T, Pereira J. The level of laboratory testing required for diagnosis or exclusion of a platelet function disorder using platelet aggregation and secretion assays. Semin Thromb Hemost, 2009; 35: 242-254.